Plasma pharmacochemistry based approach to screening potential bioactive components in Huang-Lian-Jie-Du-Tang using high performance liquid chromatography coupled with mass spectrometric detection

Hu, Yaohua; Jiang, Peng; Wang, Shuping; Yan, Shaomin; Li, Xiang; Zhang, Wei‐Dong; Liu, Runhui

doi:10.1016/j.jep.2011.08.011

Cited by 46 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical uses of HLJDT, which has been traditionally prescribed in China to treat gastrointestinal diseases, acute liver injury and cardiovascular diseases [30],[31], have now been extended to treat patients with cerebrovascular disease and vascular dementia in China and Japan [6],[7],[8]. An improved formula of HLJDT in a pill form has been approved by the Chinese State Food and Drug Administration (drug approval number Z20025356) [32]; however, the approval by the regulatory authorities for use in AD dementia in both China and Japan is still pending due to lack of efficacy data.…”

Section: Discussionmentioning

confidence: 99%

Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-β Precursor Protein Processing in Alzheimer's Disease Models

et al. 2014

View full text Add to dashboard Cite

Huanglian-Jie-Du-Tang (HLJDT) is a famous traditional Chinese herbal formula that has been widely used clinically to treat cerebral ischemia. Recently, we found that berberine, a major alkaloid compound in HLJDT, reduced amyloid-β (Aβ) accumulation in an Alzheimer’s disease (AD) mouse model. In this study, we compared the effects of HLJDT, four single component herbs of HLJDT (Rhizoma coptidis (RC), Radix scutellariae (RS), Cortex phellodendri (CP) and Fructus gardenia (FG)) and the modified formula of HLJDT (HLJDT-M, which is free of RS) on the regulatory processing of amyloid-β precursor protein (APP) in an in vitro model of AD. Here we show that treatment with HLJDT-M and its components RC, CP, and the main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation (N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal fragments of APP, soluble APP (sAPP)-α and sAPPβ-Swedish and reduced the generation of Aβ peptide in the cell lysates of N2a-SwedAPP. HLJDT-M showed more significant APP- and Aβ- reducing effects than berberine, RC or CP treatment alone. In contrast, HLJDT, its component RS and the main active compound of RS, baicalein, strongly increased the levels of all the metabolic products of APP in the cell lysates. The extract from FG, however, did not influence APP modulation. Interestingly, regular treatment of TgCRND8 APP transgenic mice with baicalein exacerbated the amyloid plaque burden, APP metabolism and Aβ production. Taken together, these data provide convincing evidence that HLJDT and baicalein treatment can increase the amyloidogenic metabolism of APP which is at least partly responsible for the baicalein-mediated Aβ plaque increase in the brains of TgCRND8 mice. On the other hand, HLJDT-M significantly decreased all the APP metabolic products including Aβ. Further study of HLJDT-M for therapeutic use in treating AD is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-β Precursor Protein Processing in Alzheimer's Disease Models

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In our former research, the qualitative and quantitative studies of HLJDD have been performed to clarify its chemical profile (Yang et al, 2013b,c). In terms of its metabolic process, apart from previous study in our team, only a limited number of metabolites in rat plasma were reported (Hu et al, 2012;Sun et al, 2006;Zuo et al, 2014). The intracorporal metabolic process of HLJDD was still not clear.…”

Section: Introductionmentioning

confidence: 90%

Metabolic fate analysis of Huang–Lian–Jie–Du Decoction in rat urine and feces by LC–IT-MS combining with LC–FT-ICR-MS: a feasible strategy for the metabolism study of Chinese medical formula

et al. 2015

View full text Add to dashboard Cite

1. Huang-Lian-Jie-Du Decoction (HLJDD) is widely used for the treatment of hypertension, diabetes, inflammation and neural system diseases in clinic. In the present study, the comprehensive metabolic profile of HLJDD was demonstrated reliably and rapidly followed by the metabolic pathway analysis of six typical pure compounds (four alkaloids, one flavonoid and one iridoid) in HLJDD using LC-IT-MS combined with high resolution LC-FT-ICR-MS. 2. Totally, 85 compounds, including 32 prototype components and 53 biotransformed metabolites were detected and characterized in the urine and feces after oral administration of HLJDD and six pure compounds to rats, respectively. Among them, 17 prototypes were identified definitely with standard references. 3. Hydroxylation, demethylation and glucuronidation reactions of alkaloids, as well as glucuronidation and sulfonation reactions of iridoids and flavonoids, were observed as the major metabolic pathways of HLJDD. Flavonoids, iridoids and their metabolites were mainly excreted from urine. However, amount of alkaloids were detected in feces. 4. In general, the distinctive metabolic process of three kinds of representative components in HLJDD was clarified. The in vivo metabolic network of HLJDD was demonstrated. Meanwhile, the investigation of representative pure compounds in metabolic study provided a valuable strategy to elucidate the full-scale metabolic fate of HLJDD. This might be helpful to understand the in vivo mechanism of Traditional Chinese medicine (TCM).

show abstract

“…A total of 12 active compounds from four medicinal plants of QSYQ were readily identified. In addition, active components and/or metabolites of DangguiShaoyao-San (DSS) [156], Fufang Danshen prescription (FDP) [157] and Huang-Lian-Jie-Du-Tang prescription (HLJDT) [158] were also analyzed using LC-MS.…”

Section: Tcm Prescriptionsmentioning

confidence: 99%

Recent developments in qualitative and quantitative analysis of phytochemical constituents and their metabolites using liquid chromatography–mass spectrometry

Guo

Chen

et al. 2013

Journal of Pharmaceutical and Biomedical Analysis

167

View full text Add to dashboard Cite

Plasma pharmacochemistry based approach to screening potential bioactive components in Huang-Lian-Jie-Du-Tang using high performance liquid chromatography coupled with mass spectrometric detection

Cited by 46 publications

References 28 publications

Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-β Precursor Protein Processing in Alzheimer's Disease Models

Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-β Precursor Protein Processing in Alzheimer's Disease Models

Metabolic fate analysis of Huang–Lian–Jie–Du Decoction in rat urine and feces by LC–IT-MS combining with LC–FT-ICR-MS: a feasible strategy for the metabolism study of Chinese medical formula

Recent developments in qualitative and quantitative analysis of phytochemical constituents and their metabolites using liquid chromatography–mass spectrometry

Contact Info

Product

Resources

About